Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Opportunities UCITS ETF 16.12.2025 FPX. IE00BYTH6238 225,002.00 USD 13,927,060.08 61.897  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 16.12.2025 GINC LN IE00BD842Y21 710,682.00 USD 40,746,532.99 57.334  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 16.12.2025 FGBL.LN IE00BYTH6121 80,186.00 USD 6,880,924.48 85.812  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 16.12.2025 FKUD IE00BD9N0445 118,031.00 GBP 3,232,417.21 27.386  ...
-

How Posh's AI Operating Procedures Redefine Banking Automation with Agentic Reasoning

BOSTON--(BUSINESS WIRE)--For years, banks and credit unions have relied on rigid automation that follows rules instead of reasoning. Today, Posh AI, the leader in conversational and agentic AI for financial institutions, announced Operating Procedures, a breakthrough system that transforms banking automation by combining intelligence, compliance, and control, powered by Posh’s upgraded reasoning engine, REALM™ 2.0. Operating Procedures mark a shift from rule-based automation to agentic AI intel...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 16.12.2025 FKU IE00B8X9NZ57 209,100.00 GBP 8,158,997.82 39.020  ...
-

MacGillivray Guest Home Workers Vote to Strike

SYDNEY, NS--(BUSINESS WIRE)--Long term care workers from MacGillivray Guest Home in Sydney, represented by Canadian Union of Public Employees (CUPE) 1562, voted 98% in favour of a strike mandate. “The long term care sector has been struggling for a long time, and this isn’t the first time we, as workers, have raised the alarm. Even just in Cape Breton, any long term care worker will tell you that their home is understaffed, that they’re finding it hard to make ends meet on the wages provided, o...
-

Hyperfine Announces Regulatory Approval of the Swoop® System in India

GUILFORD, Conn.--(BUSINESS WIRE)--Swoop® portable MRI system receives CDSCO approval in India, expanding access to advanced brain imaging in a large, fast-growing healthcare market....
-

Stratasys Partners with Novineer to Integrate NoviPath FDM Performance Simulation with GrabCAD Print Pro, Reducing Physical Testing Time, and Cost for Load-Bearing Parts

MINNETONKA, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--Stratasys Ltd. (NASDAQ: SSYS) today announced a partnership with Novineer, a generative modeling, design and simulation software company, to integrate Novineer’s NoviPath, a polymer performance simulation solution, with Stratasys’ GrabCAD Print Pro™ software. The integration gives engineers a faster, more cost-effective way to design lighter, stronger parts with predictable performance, while reducing the need for physical testing for safety...
-

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer. Kairos earned this recognition for its work advancing ENV‑105 (carotuximab), a first‑in‑class CD105‑targeting monoclonal antibody designed to modulate resistan...